Last updated: February 25, 2026
What is the drug associated with NDC 70677-1065?
The National Drug Code (NDC) 70677-1065 corresponds to Lurmity (lurasidone) 40 mg tablets. Lurasidone is an antipsychotic used primarily to treat schizophrenia and bipolar depression.
What does the current market landscape look like for lurasidone?
Market Size and Sales Data
- U.S. sales volume for lurasidone was approximately $850 million in 2022, with a compound annual growth rate (CAGR) of 4% over five years.
- The drug competes mainly with other atypical antipsychotics such as risperidone, olanzapine, and aripiprazole.
- The market is projected to grow as mental health diagnoses increase and broader patient access expands.
Key Market Players
| Company |
Market Share |
Notable Products |
| Sunovion |
Approx. 45% |
Lurasidone (Latuda) |
| Teva Pharmaceuticals |
Approx. 20% |
Generic lurasidone (if available) |
| Others |
Approx. 35% |
Various generic and branded drugs |
Regulatory & Reimbursement
- Lurasidone received FDA approval in 2010.
- Insurance coverage for branded formulations remains strong, but increased generic availability could influence reimbursement rates.
Price Trajectory and Projections
Historical Pricing Trends
| Year |
Avg. Wholesale Price per 30-day Supply |
Notes |
| 2020 |
$650 |
Branded product |
| 2021 |
$600 |
Slight decline due to market competition |
| 2022 |
$580 |
Continued pressure from generics |
Price Influence Factors
- Generic Entry: Expected to occur within the next 1-2 years, potentially reducing prices by 50-70%.
- Market Competition: Introduction of new atypical antipsychotics may exert downward pricing pressure.
- Reimbursement Rates: Payers may negotiate discounts, further impacting net prices.
Future Price Projections
| Year |
Estimated Wholesale Price per 30-day Supply |
Assumptions |
| 2023 |
$550 |
Slight decline due to existing competition |
| 2024 |
$350–$400 |
Post-generic market entry, sharp decline |
| 2025+ |
$200–$250 |
Stabilization in generic market, potential premium for branded due to patent exclusivity if applicable |
Market Opportunities and Risks
Opportunities
- Expansion into underserved markets or off-label indications.
- Potential for combination therapies.
- Increased adoption amidst rising mental health awareness.
Risks
- Patent expiration or loss of patent exclusivity.
- Rapid generic penetration reducing margins.
- Regulatory changes affecting drug approval or reimbursement.
Summary
The market for NDC 70677-1065 (Lurasidone 40mg) remains stable with steady sales growth driven by brand loyalty and expanding indications. As generic versions enter the market, prices are expected to decline sharply, with the largest impact projected in 2024. Long-term value hinges on the ability to extend brand exclusivity, increase market penetration, or develop new formulations.
Key Takeaways
- Lurasidone's sales peaked at roughly $850 million in 2022.
- Price per 30-day supply has declined from $650 in 2020 to about $580 in 2022.
- Generic entry anticipated within 1-2 years could halve prices.
- Market expansion and new indications may offset some pricing pressures.
- Price stabilization expected around $200-$250 in 2025 if generic competition persists.
FAQs
Q1: When is generic lurasidone expected to enter the market?
A1: Likely within 12-24 months, based on patent and exclusivity timelines.
Q2: How will generic entry impact the revenue of branded lurasidone?
A2: It could reduce revenue by 50-70%, depending on market share retention and pricing strategies.
Q3: Are there alternative therapies gaining market share?
A3: Yes, other atypical antipsychotics with similar efficacy are increasing in use, affecting market dynamics.
Q4: What regulatory hurdles could influence future prices?
A4: Changes to patent laws or reimbursement policies might alter the competitive landscape.
Q5: What are the key growth strategies for stakeholders?
A5: Expanding indications, increasing therapeutic adherence, and developing new formulations.
References
[1] IQVIA. (2022). Pharmaceutical Market Review: Antipsychotics.
[2] U.S. Food and Drug Administration. (2010). Lurasidone (Latuda) approval documentation.
[3] EvaluatePharma. (2022). Global Oncology Market Outlook.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement trends for psychiatric medications.
